Malignant neuroendocrine tumors are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. An investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy before they commit to a course of treatment.
Malignant neuroendocrine tumors are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. An investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy before they commit to a course of treatment.
Share this Article
Recommended